Skip to content
AnalystLens

IDEXX Laboratories 8-K Report, Material Agreement (Nov 6, 2024)

Reports
Material Agreements
Filing Date
Filed November 6, 2024
Period End
October 31, 2024
Security
IDXX
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 8-K filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report to disclose amendments to its material definitive agreements concerning the supply of dry slides for its veterinary chemistry analyzers.

These amendments, effective October 31, 2024, extend the supply agreements with Ortho-Clinical Diagnostics, Inc. through the end of 2044 for both U.S. and European operations. The key changes involve a significant extension of the contract expiration dates and modifications to the pricing structures, including adjustments to volume tiers and associated pricing over the extended contract terms. These amendments are crucial for ensuring the continued supply of a critical component for IDEXX's diagnostic instruments, providing long-term operational stability and predictability.

Key Highlights

  1. IDEXX has entered into material definitive agreements by amending its existing supply contracts with Ortho-Clinical Diagnostics, Inc.
  2. The amendments extend the expiration dates of both the U.S. and European supply agreements for dry slides to the end of 2044.
  3. These agreements are critical for the supply of dry slides used in IDEXX's veterinary chemistry analyzers.
  4. Modifications include changes to the pricing arrangements, incorporating volume tiers and associated pricing over the extended contract periods.
  5. The effective date of these amendments is October 31, 2024.
  6. This filing ensures the long-term availability of a key component for IDEXX's diagnostic product offerings.

Frequently Asked Questions

  1. What is the primary purpose of these amendments to the supply agreements?

    The primary purpose is to extend the duration of the supply agreements for dry slides used in IDEXX's veterinary chemistry analyzers and to update the pricing structures associated with these supplies.

  2. Who are the parties involved in these amended agreements?

    The parties involved are IDEXX Laboratories, Inc. and its affiliates, and Ortho-Clinical Diagnostics, Inc. (Ortho).

  3. How long have these supply agreements been extended?

    The expiration dates for both the U.S. and European supply agreements have been extended to the end of 2044.

  4. What impact do the pricing modifications have?

    The modifications to pricing arrangements include adjustments to volume tiers and associated pricing over the extended contract terms, which could affect the cost of goods for IDEXX depending on supply volumes.